Blog Archive

Showing posts with label Cambridge. Show all posts
Showing posts with label Cambridge. Show all posts

Monday, May 11, 2020

Dyno Therapeutics Raises $9M in Seed Financing


Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $9m in not previously announced seed financing round.

The round – secured when Dyno spun out of the lab of Prof. George Church of Harvard – was co-led by Polaris Partners and CRV. 

Led by Eric Kelsic, Ph.D., CEO and Co-founder, the company has also launched from stealth mode with its proprietary platform, CapsidMap™. The platform applies proprietary artificial intelligence technology to discover and design novel AAV capsids, the cell-targeting protein shell of viral vectors. CapsidMap systematically generates and then evaluates millions of new AAV variants at scale, accelerating the identification of improved AAV vectors. It uses advanced machine learning search algorithms, combined with high-throughput experiments generating massive quantities of in vivo data, to accelerate the creation of superior synthetic AAV capsids. Through its R&D and collaborations with biopharmaceutical companies, Dyno has active programs focused on novel gene therapy vectors for ophthalmic, muscle, central nervous system (CNS), and liver diseases. The platform builds on certain intellectual property developed in the lab of George Church, Ph.D., who is Robert Winthrop Professor of Genetics at Harvard Medical School (HMS) and a Core Faculty member at Harvard’s Wyss Institute for Biologically Inspired Engineering. Dyno has an exclusive option to enter into a license agreement with Harvard University for this technology. Church is a co-founder of Dyno and Chairman of the company’s Scientific Advisory Board.

Alan Crane, a co-founder of Dyno and Entrepreneur Partner at Polaris Partners, and Dylan Morris, General Partner at CRV, have joined Dyno’s board of directors, with Alan Crane serving as Dyno’s Executive Chairman.

In addition, founders include Sam Sinai, Ph.D., Lead Machine Learning Scientist, Adrian Veres, Ph.D., Scientific Advisor, and Tomas Bjorklund, Ph.D., a scientific advisor of Dyno who is Associate Professor at Lund University and a leader in AAV capsid engineering.

Source. FinSMEs, May 11, 2020

This post was brought to you by Woewoda Communications, your partner in the Canadian startup market; offering strategic communications & public relations services to Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.

Are you a pre-seed to late stage funded Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax

Friday, April 24, 2020

Inari Raises $45M in Debt Financing USA

Inari, a Cambridge, Mass.-based biotechnology company developing next-generation seeds, entered into a $45m loan and security agreement with K2 HealthVentures (K2HV), a life sciences-focused investment firm.

The funds complement Inari’s recent $89m equity raise.

The company intends to use the capital to accelerate the development and commercialization of gene-edited crops.

Led by Ponsi Trivisvavet, chief executive officer, Inari uses genetic technologies and data science to develop next-generation seeds that reduce the natural resources required to grow food.

The company was founded by Flagship Pioneering in 2016 and is headquartered in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium.

Source. FinSMEs, April 23, 2020

This post was brought to you by Woewoda Communications, your partner in the Canadian startup market; offering strategic communications & public relations services to Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.

Are you a pre-seed to late stage funded Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience. 

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.

Monday, September 2, 2019

E25Bio Raises $2.3M in Seed Funding

E25Bio, a Cambridge, Mass.-based provider of rapid, point-of-care, diagnostic technology, raised $2.3m in seed funding.
 
The round was led by The Engine, with participation from Alumni Ventures Group and angel investor Alejandro Chavez.

Founded in 2018 by Jeff Takle, CEO, based on technology developed by Drs. Irene Bosch and Lee Gehrke and licensed from MIT, E25Bio is developing rapid diagnostic test technology for at-home-use that can detect dangerous infectious diseases such as the acute febrile illnesses in minutes instead of days.

The first product is an over-the-counter test for patients appearing with fever, which is able to screen for active viruses and enables a more rapid and accurate diagnosis of infectious diseases in time to receive potentially life-saving treatment.

E25Bio has completed clinical studies and has initiated regulatory submission in its first target geographies.

Source. FinSMEs, August 26, 2010,  

***

This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.

Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.

Monday, July 1, 2019

Ultivue Raises $22 Million in Series C Funding

Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by new investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures. The investment will be used to further extend Ultivue’s leadership position primarily through the expansion of its portfolio of UltiMapper™ kits with an increasing level of product customization. Ultivue will also significantly accelerate its international market presence with increased investments in sales, field application scientists and marketing across all regions with an immediate focus on Asia.
“We are delighted to receive the backing of Northpond Ventures in addition to our existing investors as we advance the field of multiplex biomarker detection and analysis for tissue phenotyping,” said Michael Natan, CEO of Ultivue. “This latest round of financing sets the stage for substantial growth and allows us to continue developing the innovation to meet the evolving needs of our customers in translational and clinical research.”
“The fast market adoption of Ultivue’s reagents and services is making an impact in the field of immuno-oncology research and we are excited to work together with the current investors to drive forward the mission of tissue-based spatial phenotyping,” said Sharon Kedar, Co-Founder, Partner at Northpond Ventures.
About Ultivue
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.

Source. Company News Release, Ultivue, June 27, 2019

**

This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.


Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.

Friday, June 28, 2019

A Boston startup developing a nuclear fusion reactor just got a roughly $50 million boost

After twenty five years of research, scientists at the Massachusetts Institute of Technology think that they have finally cracked the code for the commercialization for nuclear fusion reactions.

Commonwealth Fusion Systems is the fruit of that research. It’s a startup building on decades of research and development that plans to harness the power of the sun to create a cleaner, stable source of energy for consumers. And the company just raised another $50 million in funding from some of the country’s deepest pocketed private investors to continue on its path to commercialization.

The company unveiled its technology and a first $64 million in financing from investors including the Italian energy company, Eni; Breakthrough Energy Ventures, the investment consortium established by the world’s richest men and women, and The Engine, MIT’s own investment vehicle for frontier technologies.

Now Future Ventures, the investment firm created by Steve Jurvetson, Khosla Ventures, Chris Sacca’s Lowercase Capital, Moore Strategic Ventures, Safar Partners, Schooner Capital and Starlight Ventures.

Commonwealth Fusion Systems began as a student project in 2014 whose goal was to reduce the cost of nuclear fusion. The class, which was taught by Dennis Whyte, who is the head of MIT’s Plasma Science and Fusion Center, came up with a new reactor technology they called the ARC (standing for “affordable, robust, compact”). That technology still came in with a few billion dollar price tag — something that would make most investors balk.

So the class went back to the drawing board, trying to come up with a minimum viable product that could produce a net energy gain (with more energy coming out of the reaction than was put in).

Net energy gain is the real sticking point for most nuclear fusion technologies. A few research institutions and projects have been able to achieve a fusion reaction, but maintaining it and getting more power out than was put in has been elusive.

In Europe, the ITER reactor, a $20 billion, multi-national effort, is 60% of the way toward its 2045 target for generating energy. Closer to home, startups like TAE Technologies and General Fusion are two other North American entrants looking at lower-cost ways to generate fusion power. And in the UK, First Light Fusion and Tokamak Energy are trying to put their own spin on fusion power.

For Bob Mumgaard, the chief executive of Commonwealth Fusion Systems, everything appears to be proceeding according to plan. on track. “CFS is on track to commercialize fusion and deliver an inherently safe, globally scalable, carbon-free, and limitless energy source,” he said in a statement.

Commonwealth Fusion expects to have its smallest possible reactor built by 2025 thanks to the research that MIT has done on proprietary magnet technology that the company uses to confine its nuclear reaction. In fact, most of the financing will go toward construction of the full scale magnet technology Commonwealth Fusion uses to contain its reactions.

The ultimate goal is to build a fusion reactor that can generate 50 megawatts of energy either as heat or to create electricity using a steam turbine.

Unlike fission reactors, which have significant environmental risks, a fusion power plant would be regulated in much the same way as any industrial facility, says Mumgaard. “The hazard profile of fusion continues to put it in [the category of] an industrial facility. The laws exist, but we haven’t gone out and built the plant yet, so no one has the precedent.”

Mumgaard envisions a 200 megawatt scale reactor that could slot into the place of a wind farm or solar power plant.

“You have to keep track of moving towards vs. going to get to,” he says. “The consensus is we do not have a solution in hand for deep decarbonization of the electricity grid. if you look at where the biggest gains even in renewables.. the biggest gains are in the utility scale were you’re talking hundreds of megawatts of power per site.”

Renewable energy alone will not be enough to meet the demand that’s coming from modern metropolises, according to Mumgaard. “There is huge demand for concentrated energy to power the modern lifestyle.

Public opinion on the issue is increasingly divided — especially among nuclear opponents who count themselves as part of the Sunrise Movement behind the Green New Deal that’s been the talk of the town in energy policy circles. But most energy analysts  argue for a blended approach and say that to get to zero carbon emissions (the ultimate goal for the scientific community), nuclear power will need to be incorporated into the mix.

“We have been looking for the right clean energy investment opportunity in fusion for the past 20 years, said Steve Jurvetson, chief executive of Future Ventures, in a statement. “We wanted a company that was ready to make a business of fusion and we have finally found it with Commonwealth Fusion Systems. The hard science from which their approach is based has been proven by this team as well as leaders in the field around the world.  With some clever engineering, CFS is ready to harness the power of the solar cycle to change the world and usher in the era of clean baseload energy generation for the betterment of all.”

Source. TechCrunch, Johnathan Bieber, June 27, 2019

***

This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.


Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax




Wednesday, April 24, 2019

Sherlock Biosciences raises $31M to apply CRISPR technology to diagnostics


By Alaric Dearment

A startup planning to apply CRISPR technology to diagnostics has raised its first major round of venture capital financing a month after its founding.

Cambridge, Massachusetts-based Sherlock Biosciences said Tuesday that it had raised $31 million in a Series A round, led by Northpond Ventures and Baidu Ventures, with additional contributions from the Open Philanthropy Project and other investors. The company was launched last month with $35 million in initial financing, which included a $17.5 million non-dilutive grant and another investment by the Open Philanthropy Project.

The company’s founders are several veterans of the diagnostics industry and gene-editing science, including CRISPR pioneer Feng Zhang of The Broad Institute.

Its stated desire is to use the new funding to “disrupt” diagnostics by developing molecular diagnostics that can rapidly deliver accurate and inexpensive results in areas like oncology, infectious diseases, at-home testing, low-resource settings and agriculture.

The company has in-licensed two technology platforms from The Broad and Harvard University’s Wyss Institute for Biologically Inspired Engineering. From The Broad, it has licensed SHERLOCK, developed by Zhang and others, and from Wyss it has licensed the molecular diagnostics platform INSPECTR.

SHERLOCK – whose name is derived from “specific high-sensitivity enzymatic reporter unlocking” – works by amplifying genetic sequences and programming a CRISPR molecule to detect specific genetic signatures in samples, releasing a signal when those signatures are detected. According to the company, SHERLOCK is able to detect the unique genetic “fingerprints” of almost any DNA or RNA sequence in an organism of pathogen. The INSPECTR acronym is derived from “internal splint-pairing expression cassette translation reaction.” It works through synthetic biology and synthetic gene networks and enables the creation of instrument-free diagnostic devices.

The company’s application of CRISPR to diagnostics is a departure from the more well-known uses of the technology, which have primarily focused on therapeutic gene-editing. In February, a Phase I/II clinical trial of a therapy developed using the technology in beta-thalassemia, run by Boston-based Vertex Pharmaceuticals and Switzerland’s CRISPR Therapeutics, dosed its first patient. And last week, a Phase I clinical trial at the University of Pennsylvania of a cell therapy sponsored by Mustang Bio dosed its first two patients, one with multiple myeloma and one with a sarcoma.

Source. Medcity News, Alaric Dearment, April 23, 2019

***

This post was brought to you by Woewoda Communications, your partner in the Canadian private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.

Are you a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.

Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa, and Halifax.

Tuesday, March 19, 2019

Imara Closes $63M Series B funding round for blood disorder development

By Alaric Dearment

Cambridge, Massachusetts-based Imara said Monday that it had raised the $63 million Series B funding round, led by new investors OrbiMed and Arix Bioscience. Other participants in the round included RA Capital, Rock Springs Capital and existing investors New Enterprise Associates, Pfizer Venture Investments, Lundbeckfonden Ventures, Bay City Capital and Alexandria Venture Investments.
Imara said it planned to use the money to fund development of its lead product candidate, IMR-687, which is currently in a Phase IIa trial in sickle cell disease, and move it into later-stage clinical trials. It also plans to fund the drug’s development as a potential treatment for beta-thalassemia, another blood disorder, and expand its pipeline.
“This is a transformative financing for Imara – one that will allow us to greatly expand our sickle cell disease clinical development, widen our reach into thalassemia and build an exciting pipeline,” CEO Rahul Ballal said in a statement. “We are pleased to be working with leading investors who share our vision for creating a company that helps change the lives of patients living with SCD and other hemoglobinopathies.”

IMR-687 is an inhibitor of phosphodiesterase-9, working on the same pathway as hydroxyurea, a generic chemotherapy drug commonly used to treat blood disorders and blood cancers. The difference, according to the company, is that it doesn’t have the safety issues that come with hydroxyurea. Hydroxyurea’s label carries a boxed warning for severely reduced blood counts and carcinogenicity.
The company announced preclinical and Phase I data in September 2017 showing that IMR-687’s mechanism of action could be effective against the red and white blood cell pathologies associated with SCD and that it could be safely dosed in humans at levels shown as effective in preclinical models.

IMR-687 is an inhibitor of phosphodiesterase-9, working on the same pathway as hydroxyurea, a generic chemotherapy drug commonly used to treat blood disorders and blood cancers. The difference, according to the company, is that it doesn’t have the safety issues that come with hydroxyurea. Hydroxyurea’s label carries a boxed warning for severely reduced blood counts and carcinogenicity.
The company announced preclinical and Phase I data in September 2017 showing that IMR-687’s mechanism of action could be effective against the red and white blood cell pathologies associated with SCD and that it could be safely dosed in humans at levels shown as effective in preclinical models.

Source. Medcitynews, Alaric Dearment, March 18, 2019

About  Woewoda Communications

Woewoda Communications is one of Canada’s leading strategic communications and public relations firms. Located in Langley BC, the agency has built its reputation on creating and implementing integrated solutions that delivers what its clients value most: meaningful, positive, measurable, and impactful PR campaigns.

 Our mission is to provide clients with inspired, integrated communications service. Our teams of PR professionals work with the Investment Community and Start-ups to design, implement, and manage communication strategies that help our clients bridge the information gap between them and their stakeholders.

Our PR services include Campaign building, Media PR, Community PR, Relationship PR, Venture Capital PR, Start-up PR, Private Equity PR, and Investor Relation Services (IR).

Whether its campaign building, media interaction, promoting a Venture Capital (VC) or a Private Equity (PE) and their investment portfolio, positioning a Start-up company, improving a company’s relationship with their community, organizing a major business event, or reaching out to investors, we have the PR team that can help our clients reach their goals.

Our Services. Strategic Communications, Public Relations and Investor Relations

Clients. Venture Capitalists, Private Equity Investors, Family Offices, Endowments/Trusts, Angel Investors, and Start-ups

Sectors. Information communication technology, life sciences, healthcare, artificial intelligence, robotics, clean energy, financial technology, internet of things, blockchain technology, and agribusiness

"We work with General Partners, Limited Partners, Corporate Investors and  Presidents of Start-ups in Canada and the United States".

Small Business Finance Presentation: Creating Your Money Map

  Small Business Finance Presentation Creating Your Money Map  Title  Small Business Finances - Creating your Money Map Descriptio...